Gene sequencing test maker Illumina Inc. said Sunday that its board has accepted the resignation of its CEO and director, Francis deSouza, effective immediately.
Charles Dadswell, senior vice president and general counsel, has been named interim CEO, while the board conducts a search for a new CEO. Illumina said deSouza, who has been with the company since 2013 and was named CEO three years later, will stay on in an advisory capacity until July 31.
“Illumina’s technology remains at the forefront of DNA sequencing and has continued to set the pace for the industry,” Illumina's board chair, Stephen P. MacMillan, said in a statement. “We are confident Illumina can continue to execute on its goals, while we conduct and complete a CEO search process.”
The company, based in San Diego, said the board is looking at internal and external candidates.
The resignation comes as Illumina has been locked in a monthslong heated battle with activist investor Carl Icahn, over its $7.1 billion acquisition of cancer test maker Grail that has faced regulatory hurdles. Icahn had urged shareholders to vote out its chairman, John Thompson, and deSouza. Company shareholders voted out Thompson in late May.
Federal Reserve governor Lisa Cook late Wednesday said she wouldn’t leave her post after Trump on social media called on her to resign over an accusation from one his officials that she committed mortgage fraud.
Explore how Guident’s cutting-edge software is shaping the future of autonomous vehicles with CEO Harald Braun. Safety, control & AI at the wheel of innovation.
Wondercraft co-founder Oskar Serrander discusses the booming AI audio industry, deepfake risks, and the growing market for synthetic, AI-generated content.
Comerica’s Chief Economist Bill Adams unpacks U.S. retail sales, job growth, and the resurgence of market volatility—and what it all signals for the economy.
Saar Yoskovitz, CEO of Augury, shares how the company delivers AI infrastructure that Fortune 500s rely on to boost efficiency, reliability, and scale.
